The Value of Neutrophil Lymphocyte Ratio in Predicting the Degree of Insulin Resistance and β Cell Dysfunction in Type 2 Diabetic Patients
Eman Youssef Moursy,
Azza Abd El-Kareem Ismael,
Reham Fadl Hassan Mouftah,
Eglal Saad Ghanem El-Tahan
Issue:
Volume 4, Issue 2-1, March 2016
Pages:
1-4
Received:
24 August 2015
Accepted:
25 August 2015
Published:
25 October 2015
DOI:
10.11648/j.ajim.s.2016040201.11
Downloads:
Views:
Abstract: Objective:Insulin resistance and progressive pancreatic β-cell failure are key factors in the development of type 2 diabetes.The aim of the present study was to define the relationship between Neutrophil Lymphocyte Ratio (NLR) and the degree of insulin resistance and β cell dysfunction in Type 2Diabetus Mellitus.Methods: This study was carried out on seventy diabetic patient attended the outpatient clinic of the diabetes and metabolism unit in Alexandria Main University Hospital (AMUH)and thirty t healthy subjects with matched age, sex and socioeconomic status as a control group. Subjects were interviewed in order to collect data using predesigned questionnaire, anthropometric measures were measured, blood samples were collected from each subject for chemical analysis. Results: NLR was higher in diabetic subjects than non-diabetic one. NLR showed significant positive correlation with HOMA-IR and no significant negative correlation with HOMA-β.Conclusion: the relation between inflammation and adipose tissue is extremely complex in diabetic patients. However, simple calculation of NLR and measurement of waist circumference can reveal inflammation in the diabetic population.
Abstract: Objective:Insulin resistance and progressive pancreatic β-cell failure are key factors in the development of type 2 diabetes.The aim of the present study was to define the relationship between Neutrophil Lymphocyte Ratio (NLR) and the degree of insulin resistance and β cell dysfunction in Type 2Diabetus Mellitus.Methods: This study was carried out ...
Show More
Study of Serum Osteoprotegerin Level in Uremic Patients and Its Relation to Renal Bone Disease
Mohamed Magdy,
Mona Mostafa,
Heba Elshair,
Hesham Elghoneimy
Issue:
Volume 4, Issue 2-1, March 2016
Pages:
5-12
Received:
11 September 2015
Accepted:
13 September 2015
Published:
25 October 2015
DOI:
10.11648/j.ajim.s.2016040201.12
Downloads:
Views:
Abstract: Introduction: Bone disease associated with renal failure is termed renal osteodystrophy and is quite heterogeneous. Microscopic examination of a bone biopsy specimen is still considered the gold standard for diagnosis. Nevertheless, recent studies suggest that serum markers of bone formation and resorption may be of additional help in assessing bone turnover. Osteoprotegerin (OPG) and osteoprotegerin ligand (OPGL) constitute a complex mediator system involved in the regulation of the resorption process in bone. The present work aimed at studying the serum levels of osteoprotegerin and relation of osteoprotegerin to PTH and x-ray features of renal osteodystrophy has been studied. Subjects and methods: The present study was conducted on three groups Group I: 20 patients with chronic kidney disease( CKD) divided into two subgroups: Group Ia: 10 patients in stage 2 CKD (GFR of 60-89 ml/min) and stage 3 CKD (GFR of 30-59 ml/min).Group Ib: 10 patients in stage 4 CKD (GFR of 15-29 ml/min) and stage 5 CKD (GFR of <15 ml/min).Group II: 20 patients on maintenance hemodialysis for more than one year They were divided into two subgroups: Group IIa: 10 patients with intact PTH < 300 pg/ml.Group IIb: 10 patients with intact PTH > 300 pg/ml.Group III:10 age and sex matched healthy controls.Investigations will include measurements of Serum calcium,phosphorus, serum alkaline phosphatase,serum intact PTHand Assay of serum osteoprotegerin by enzyme linked immunosorbent assay (ELISA) technique. Results: Serum levels of OPG were higher in patients with CKD and patients on maintenance hemodialysis than healthy control. Serum levels of OPG were significantly higher in stage 4 and 5 CKD than in stage 2 and 3 CKD. Conclusions: Serum OPG level could be of help in the non-invasive diagnosis and monitoring of bone turn over state in patients with CKD.
Abstract: Introduction: Bone disease associated with renal failure is termed renal osteodystrophy and is quite heterogeneous. Microscopic examination of a bone biopsy specimen is still considered the gold standard for diagnosis. Nevertheless, recent studies suggest that serum markers of bone formation and resorption may be of additional help in assessing bon...
Show More
Serum Chemerin Level: Does It Have a Role in Progression of Diabetic Nephropathy
Iman E. El-Gohary,
Azza Abedl-Karim,
Doaa I. Hashad
Issue:
Volume 4, Issue 2-1, March 2016
Pages:
13-17
Received:
24 October 2015
Accepted:
26 October 2015
Published:
30 November 2015
DOI:
10.11648/j.ajim.s.2016040201.13
Downloads:
Views:
Abstract: Background: Diabetic nephropathy has become the leading cause of end-stage renal failure in Europe, the United States and Japan (25-44%). Chemerin is a chemoattractant expressed in white adipose, liver and lung tissues. Chemerin is shown to be associated with inflammation which is involved in the pathogenesis of diabetic nephropathy. The aim of the present work is to estimate serum chemerin level and to correlate its level in the patients with the stage of the diabetic nephropathy disease. Patients and Methods: The present study included 60 subjects who were divided into 4 groups Group I: included 15 diabetic patients with norm albuminuria Group II: included 15 diabetic patients with microalbuminuria Group III: included 15 diabetic patients with macroalbuminuria Group IV: included 15 normal subjects as a control group. All patients and controls were subjected to estimation of body mass index. Blood urea, serum creatinine and estimated GFR, Urinary albumin to urinary creatinine ratio, complete lipid profile (LDL, HDL, TG) and Serum chemerin level by ELIZA. Results: Serum chemerin level was higher in diabetic than non-diabetic persons and was higher in patients with macroalbuminuria than those with normo and microalbuminuria and its level is correlated with markers of impaired renal function. Conclusion: chemerin could have a role in progression of diabetic nephropathy or its level could be elevated due to impaired renal excretion which should be further investigated.
Abstract: Background: Diabetic nephropathy has become the leading cause of end-stage renal failure in Europe, the United States and Japan (25-44%). Chemerin is a chemoattractant expressed in white adipose, liver and lung tissues. Chemerin is shown to be associated with inflammation which is involved in the pathogenesis of diabetic nephropathy. The aim of the...
Show More
Study of the Role of Nicotinamide Phosphoribosyl Transferase/Visfatin in Egyptian Patients with Systemic Lupus Erythematous and Lupus Nephritis
Eman. H. El Sayed,
Mohamed S. Brakat,
Wael M. Diab,
Mona H. Abd Elmaged,
Manal. Y. Tayel,
Ragaa. A. Ramadan
Issue:
Volume 4, Issue 2-1, March 2016
Pages:
18-23
Received:
26 January 2016
Accepted:
27 January 2016
Published:
29 February 2016
DOI:
10.11648/j.ajim.s.2016040201.14
Downloads:
Views:
Abstract: Introduction: Lupus nephritis (LN) is common and carries a high burden of morbidity in SLE patients. The adipokine ‘‘visfatin’’is highly expressed in visceral fat, exerts several pro inflammatory functions and was demonstrated as a marker of endothelial dysfunction (ED) in chronic kidney disease (CKD). Aim of the work: to evaluate the state of serum visfatin in SLE patients and to detect its possible correlation to disease activity and kidney affection. Also, to define a possible correlation between the level of visfatin before and after a treatment regimen of combined mycophenolate mofetil and corticosteroids. Patients and methods: visfatin was assayed using enzyme-linked immunosorbent assay (ELISA), chemical and immunological markers of SLE and LN were measured in 50 SLE patients (included 25 patients with LN and 25 patients without LN), and compared with 25 age and sex matched healthy controls. Disease activity was assessed using SLE Disease Activity Index (SLEDAI). Renal biopsies were taken from LN subgroup and were classified according to the modified WHO classification. [1] Results: There was statistically highly significant difference (P < 0.001) as regards serum visfatin between patients (mean 8.31 ± 3.60, median 8, 64), and controls (mean 4.60 ± 2.01), serum visfatin showed significantly higher levels in LN compared to the non-lupus nephritis group (mean 8.78 ± 3.81 ng/ml,) versus (mean 7.85 ± 3.38 ng/ml,). Also, visfatin level was significantly higher among the active (mean 9.30 ± 3.14,) compared to the inactive group (mean 4.37 ± 2.46). Visfatin had a highly significant positive correlation with SLEDAI, disease duration, corticosteroids treatment duration, ESR and CRP. Also, a significant inverse correlation existed between visfatin, WBCs and Platelets count, correlation studies between visfatin level and low level of C3, C4 were significant. The correlation between serum visfatin level and Carotid artery intima media thickness by carotid Doppler imaging was also significant. There was a significant decrease (P= 0.041) between pre-treatment visfatin level and post treatment level after 3 months of MMF and high dose CS treatment, Visfatin mean decreased from (8.78 ± 3.81 ng/ml) to (8.29 ± 3.44 ng/ml). Conclusion: visfatin is closely associated with SLE activity especially with lupus nephritis revealing the promising role of this adipokine in SLE activity measurement and prediction of renal involvement in SLE patients.
Abstract: Introduction: Lupus nephritis (LN) is common and carries a high burden of morbidity in SLE patients. The adipokine ‘‘visfatin’’is highly expressed in visceral fat, exerts several pro inflammatory functions and was demonstrated as a marker of endothelial dysfunction (ED) in chronic kidney disease (CKD). Aim of the work: to evaluate the state of seru...
Show More
